This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Randomized Trial With Trastuzumab Versus Observation in Breast Cancer Patients

This study has been completed.
Information provided by:
University Hospital of Crete Identifier:
First received: January 30, 2007
Last updated: July 20, 2011
Last verified: January 2008
Epithelial tumor cells can be detected in the bone marrow and/or the peripheral blood [disseminated and circulating tumor cells, (DTCs) and (CTCs) respectively] of otherwise metastases-free patients with early breast cancer. Several studies have shown that the presence of these cells is an independent factor associated with an increased incidence of early disease relapse and disease-related death. In almost 50% of the patients, adjuvant chemotherapy cannot eliminate these occult tumor cells and this is also associated with a higher probability of early relapse and death. In 60-70% of the patients, DTCs and/or CTCs express the HER2/c-neu molecule and one or two administrations of their monoclonal antibody trastuzumab (HERCEPTIN) could eliminate these cells for a period ranging from 3-12 months.

Condition Intervention Phase
Breast Cancer Drug: Trastuzumab Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Pilot Randomized Phase II Study of Adjuvant Administration of Trastuzumab (HERCEPTIN) Versus Observation After the Completion of Adjuvant Chemotherapy and Radiotherapy in Patients With Stage I-III Breast Cancer Who Have Detectable Disseminated and/or Circulating Tumor Cells (DTCs and/or CTCs) in the Bone Marrow or/and the Peripheral Blood Before or/and After the Completion of Adjuvant Treatment

Resource links provided by NLM:

Further study details as provided by University Hospital of Crete:

Primary Outcome Measures:
  • Compare the disease-free interval of patients with early-stage breast cancer [ Time Frame: 3 years ]

Secondary Outcome Measures:
  • Elimination of CK-19 mRNA-positive CTCs. [ Time Frame: Assessment of CK-19 mRNA CTCs every 3 months ]

Enrollment: 75
Study Start Date: February 2003
Study Completion Date: December 2007
Primary Completion Date: December 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Drug: Trastuzumab
Trastuzumab,first administration at the dose of 8mg/Kg IV, subsequent administrations at the dose of 6mg/Kg IV,every 3 weeks for 6 cycles
Other Name: Herceptin
No Intervention: 2
Follow up

Detailed Description:
This pilot trial will compare the efficacy of the anti-HER2/erb-B2 monoclonal antibody trastuzumab (HERCEPTIN) given after the completion of the standard adjuvant chemotherapy and radiotherapy versus observation in patients with stage I-III operable breast cancer who have detectable cytokeratin-19 (CK-19) mRNA-positive tumor cells in the bone marrow or the peripheral blood before and/or after the adjuvant treatment.

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age >= 18 years.
  • Performance status (World Health Organization [WHO]) < 3
  • Adequate bone marrow function (absolute neutrophil count > 1000/mm^3, platelet count > 100000/mm^3, hemoglobin > 9 gr/mm^3)
  • Adequate liver (bilirubin < 1.5 times upper limit of normal and SGOT/SGPT < 2 times upper limit of normal) and renal function ( creatinine < 2 mg/dl)
  • Adequate cardiac function (left ventricular ejection fraction [LVEF] > 50%).
  • Informed consent
  • Histologically or cytologically confirmed breast adenocarcinoma
  • Prior surgical excision of the primary breast tumor
  • Prior completion of standard adjuvant chemotherapy and/or radiotherapy
  • Locally advanced disease after the completion of neo-adjuvant chemotherapy, surgical excision and radiotherapy provided that there was no evidence of local or metastatic disease
  • Absence of any clinical or laboratory evidence of metastatic disease
  • Detection of CTCs and/or DTCs (when it could be feasible) before the initiation and/or after the completion of adjuvant chemotherapy and/or radiotherapy
  • Expression of HER2/c-neu on the primary tumor is not mandatory

Exclusion Criteria:

  • Other invasive malignancy within the past 5 years except nonmelanoma skin cancer
  • Other concurrent uncontrolled illness
  • Psychiatric illness or social situation that would preclude study compliance
  • Pregnant or nursing
  • Positive pregnancy test
  • History of allergic reaction attributed to trastuzumab (HERCEPTIN)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00429247

University Hospital of Crete
Heraklion, Crete, Greece, 71110
Sponsors and Collaborators
University Hospital of Crete
Principal Investigator: Vassilis Georgoulias, MD University Hospital of Crete, Dep of Medical Oncology
  More Information

Responsible Party: V.Georgoulias, University Hospital of Crete Identifier: NCT00429247     History of Changes
Other Study ID Numbers: CT/01.60
Study First Received: January 30, 2007
Last Updated: July 20, 2011

Keywords provided by University Hospital of Crete:
Occult tumor cells
Micrometastatic cells
Completion of Adjuvant Treatment

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Antineoplastic Agents processed this record on September 20, 2017